CAMC is the first health system in southern West Virginia to implant the Barostim™ Baroreflex Activation Therapy, the world’s first FDA–approved heart failure device to use neuromodulation, which is the power of the brain and nervous system, to improve the symptoms of systolic heart failure. This advanced therapy was designed to treat heart failure patients who have had little to no success with other proven treatment options.
“This innovative, minimally-invasive procedure involves placing a small device under the skin of the chest that sends electrical signals to the carotid artery in the neck. These signals stimulate the baroreceptors, which are pressure sensors that send information to the brain about blood pressure and heart rate,” said Shadi Abu-Halimah, MD, Vascular Surgeon at the CAMC Vascular Center of Excellence. “We are thrilled to offer this groundbreaking technology for our patients. To get patients back to their normal routine and improve their quality of life is incredible.”
For more information, visit camc.org/VascularCare
